Merck & Co.’s Executive Vice President (EVP) and President of Human Health, Frank Clyburn, will leave the company on February 1, 2022, to become Chief Executive Officer at IFF.

Mr. Clyburn joined Merck in 2008 and held several leadership positions. In March 2021, he was named President of Human Health. Previously, he served as Chief Commercial Officer for Human Health and was the President of Merck’s global oncology business. Merck says it will announce the new leadership of its Human Health in the coming weeks (as reported on January 20, 2022). 

At IFF, Mr. Clyburn will succeed Andreas Fibig as CEO and become a member of the IFF Board of Directors, effective February 14, 2022.

IFF has decided to separate the Chairman and the CEO roles. Dale Morrison, a long-standing IFF Director, will assume the role of Non-Executive Chairman of the Board of Directors, effective on February 14, 2022. Ed Breen, IFF Director, will remain on the Board as an Independent Director, and the company will no longer have the Lead Independent Director role.

Source: Merck & Co. and IFF